Joint publications of EUTox to which at least two member groups contributed.


2018 254.
Krochmal M, Schanstra JP, Mischak H.: Urinary peptidomics in kidney disease and drug research.Expert Opin Drug Discov. 2018 Mar;13(3):259-268.
Gayrard N, Ficheux A, Duranton F, Guzman C, Szwarc I, Vetromile F, Cazevieille C, Brunet P, Servel MF, Argilés À, Le Quintrec M. Correction: Consequences of increasing convection onto patient care and protein removal in hemodialysis.PLoS One. 2018 Jan 2;13(1)
2017 252.
Krochmal M, Kontostathi G, Magalhães P, Makridakis M, Klein J, Husi H, Leierer J, Mayer G, Bascands JL, Denis C, Zoidakis J, Zürbig P, Delles C,Schanstra JP, Mischak H, Vlahou A.Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.Sci Rep. 2017Nov 9;7(1):15160.
Evenepool P, Glorieux G, Meijers B.: p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. Kidney Int. 2017 Dec;92(6):1323-1324.
Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney Int Rep. 2017 Nov;2(6):1066-1075.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, van Biesen W, Nagler E, Gonzalez-Espinoza L, Ortiz A; Hyponatraemia Guideline Development Group. Hyponatraemia diagnosis and treatment clinical practice guidelines. Nefrologia. 2017 Jul - Aug;37(4):370-380.
Krochmal M, Cisek K, Filip S, Markoska K, Orange C, Zoidakis J, Gakiopoulou C, Spasovski G, Mischak H, Delles C, Vlahou A, Jankowski J. Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. Sci Rep. 2017 Aug 22;7(1):9091
247. Argilés À, Rodriguez M, Ortiz A. Is Plasma Proteomics Able to Provide Alternative Paths to Better Understand Hypertension? Hypertension. 2017 Aug;70(2):250-252.
246. Htun NM, Magliano DJ, Zhang ZY, Lyons J, Petit T, Nkuipou-Kenfack E, Ramirez-Torres A, von Zur Muhlen C, Maahs D, Schanstra JP, Pontillo C, Pejchinovski M, Snell-Bergeon JK, Delles C, Mischak H, Staessen JA, Shaw JE, Koeck T, Peter K. Prediction of acute coronary syndromes by urinary proteome analysis. PLoS One. 2017 Mar 8;12(3):e0172036.
Chinnappa S, White E, Lewis N, Baldo O, Tu YK, Glorieux G, Vanholder R, El Nahas M, Mooney A. Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2017 May 19.
Vanholder R, Gryp T, Glorieux G. Urea and chronic kidney disease: the comeback of the century? (in uraemia research).Nephrol Dial Transplant. 2017 Apr 12.
Boelaert J, Lynen F, Glorieux G, Schepers E, Neirynck N, Vanholder R. Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. Anal Bioanal Chem. 2017 Mar;409(8):2201-2211.
Ficheux A, Gayrard N, Duranton F, Guzman C, Szwarc I, Vetromile F, Brunet P, Servel MF, Argilés A. A reliable method to assess the water permeability of a dialysis system: the global ultrafiltration coefficient. Nephrol Dial Transplant. Feb 1;32(2):364-370, 2017
Gayrard N, Ficheux A, Duranton F, Guzman C, Szwarc I, Vetromile F, Cazevieille C, Brunet P, Servel MF, Argilés À, Le Quintrec M. Consequences of increasing convection onto patient care and protein removal in hemodialysis.PLoS One. Feb 6;12(2), 2017
Nkuipou-Kenfack E, Schanstra JP, Bajwa S, Pejchinovski M, Vinel C, Dray C, Valet P, Bascands JL, Vlahou A, Koeck T, Borries M, Busch H, Bechtel-Walz W, Huber TB, Rudolph KL, Pich A, Mischak H, Zürbig P. The use of urinary proteomics in the assessment of suitability of mouse models for ageing. PLoS One. Feb 15;12(2), 2017
239. Siebert S, Porter D, Paterson C, Hampson R, Gaya D, Latosinska A, Mischak H, Schanstra J, Mullen W, McInnes I.Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Sci Rep. Jan 16;7:40473, 2017
2016 238. Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant. 2016 Oct 5.
237. Ortiz A, Husi H, Gonzalez-Lafuente L, Valiño-Rivas L, Fresno M, Sanz AB, Mullen W, Albalat A, Mezzano S, Vlahou T, Mischak H, Sanchez-Niño MD. Mitogen-Activated Protein Kinase 14 Promotes AKI. J Am Soc Nephrol. Sep 12, 2016
236. Pavlenko D, van Geffen E, van Steenbergen MJ, Glorieux G, Vanholder R, Gerritsen KGF, Stamatialis D. New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Nature Scientific reports,in press,2016
235. Chevtchik NV, Fedecostante M, Jansen J, Mihajlovic M, Wilmer M, Rüth M, Masereeuw R, Stamatialis D. Upscaling of a living membrane for bioartificial kidney device. Eur J Pharmacol. Jul 6, 2016
234. Klein J, Bascands JL, Mischak H, Schanstra JP. The role of urinary peptidomics in kidney disease research. Kidney Int., 89,539-545, 2016
233. Jansen J, Fedecostante M, Wilmer MJ, Peters JG, Kreuser UM, van den Broek PH, Mensink RA, Boltje TJ,Stamatialis D, Wetzels JF, van den Heuvel LP, Hoenderop JG,Masereeuw R. Bioengineered kidney tubules efficiently excrete uremic toxins. Sci Rep. 2016 May 31, 2016
232. Metzger J, Mullen W, Husi H, Stalmach A, Herget-Rosenthal S, Groesdonk HV, Mischak H, Klingele M. Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study.Crit Care. May 26;20(1):157, 2016
231. Jansen J, De Napoli IE, Fedecostante M, Schophuizen CMS, Chevtchik NV, Wilmer MJ, van Asbeck AH, Croes HJ, Pertijs JC, Wetzels JFM, Hilbrands LB, van den Heuvel LP, Hoenderop JG, Stamatialis D, Masereeuw R. Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations. Nature Scientific reports, 6 ( 26715), 2016
230. Chevtchik NV, Fedecostante M, Jansen J, Mihajlovic M, Wilmer M, Rüth M, Masereeuw R, Stamatialis D. Bioengineered kidney tubules efficiently excrete uremic toxins. Nature Scientific reports, 6 (16702), 2016
229. Vanholder R, Glorieux G, Massy ZA. Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations? Nephrol Dial Transplant. Apr 6, 2016
228. Krochmal M, Fernandes M, Filip S, Pontillo C, Husi H, Zoidakis J, Mischak H, Vlahou A, Jankowski J. PeptiCKDdb-peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. Database (Oxford). Sep 2016.
227. Duranton F, Jankowski J, Więcek A, Argilés À. On the discovery of UREA. Identification, synthesis and observations that let to establishing the first uraemic retention solute. G Ital Nefrol. Feb;33 Suppl 66:33.S66.16, 2016
226. Smith A, L'Imperio V, De Sio G, Ferrario F, Scalia C, Dell'Antonio G, Pieruzzi F, Pontillo C, Filip S, Markoska K, Granata A, Spasovski G, Jankowski J, Capasso G, Pagni F, Magni F. α-1-Antitrypsin detected by MALDI imaging in the study of glomerulonephritis: Its relevance in chronic kidney disease progression. Proteomics.Jun;16(11-12):1759-66, 2016
225. Krieter DH, Devine E, Körner T, Rüth M, Wanner C, Raine M, Jankowski J, Lemke HD. Haemodiafiltration at increased plasma ionic strength for improved proetin-bound toxin removal.. Acta Physiol (Oxf). Jun 4, 2016
224. Carrick E, Vanmassenhove J, Glorieux G, Metzger J, Dakna M, Pejchinovski M, Jankowski V, Mansoorian B, Husi H, Mullen W, Mischak H, Vanholder R, Van Biesen W.Development of a MALDI MS-based platform for early detection of acute kidney injury. Proteomics Clin Appl. Jul;10(7):732-42, 2016
223. Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJ, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J. A urinary proteome - based classifier for the early detection in glomerular filtration. Nephrol Dial Transplant. Jul 6, 2016
222. Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT, Chapman AB, Kistler AD.Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. Jul 5 , 2016
221. Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, MischakPeng XR, Bascands JL, Schanstra JP. Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int., Aug 12, 2016
220. Latosinska A, Makridakis M, Frantzi M, Borràs DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS, Jankowski V, Mischak H, Vlahou A. Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Sci Rep. May 11;6:25619, 2016
219. Bhat A, Mokou M, Zoidakis J, Jankowski V, Vlahou A, Mischak H. BcCluster: A Bladder Cancer Database at the Molecular Level. Bl Cancer. 2016 Jan 7;2(1):65-76
218. Duranton F, Duny Y, Szwarc I, Deleuze S, Rouanet C, Selcer I, Maurice F, Rivory JP, Servel MF, Jover B, Brunet P, Daurès JP, Argilés À. Early changes in body weight and blood pressure are associated with mortality in incident dialysis patients.Clin Kidney J. Apr;9(2):287-94, 2016
217. Liabeuf S, Desjardins L, Massy ZA, Brazier F, Westeel PF, Mazouz H, Titeca-Beauport D, Diouf M, Glorieux G, Vanholder R, Jaureguy M, Choukroun G. Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes.Circ J. Feb 25;80(3):722-30,2016
216. Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. Am J Kidney Dis. Mar;67(3),2016
215. Duranton F, Jankowski J, Więcek A, Argilés À. On the discovery of UREA. Identification, synthesis and observations that let to establishing the first uraemic retention solute. G Ital Nefrol. Feb;33(S66),2016
2015 214. Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra JP, Jankowski J, Mischak H, Argilés À, Vanholder R, Vlahou A, Klein J.New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis.Nephrol Dial Transplant. Nov;30(11), 2015
213. Zoccali C, Amodeo D, Argiles A, Arici M, D'arrigo G, Evenepoel P, Fliser D, Fox J, Gesualdo L, Jadoul M, Ketteler M, Malyszko J, Massy Z, Mayer G, Ortiz A, Sever M, Vanholder R, Vinck C, Wanner C, Więcek A.The fate of triaged and rejected manuscripts.Nephrol Dial Transplant. Dec;30(12), 2015
212. Latosinska A, Vougas K, Makridakis M, Klein J, Mullen W, Abbas M, Stravodimos K, Katafigiotis I, Merseburger AS, Zoidakis J, Mischak H, Vlahou A, Jankowski V. Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis. PLoS One. Sep 2;10(9), 2015
211. Nkuipou-Kenfack E, Bhat A, Klein J, Jankowski V, Mullen W, Vlahou A, Dakna M, Koeck T, Schanstra JP, Zürbig P, Rudolph KL, Schumacher B, Pich A, Mischak H. Identification of ageing-associated naturally occurring peptides in human urine. Oncotarget. Sep 29, 2015
210. Schophuizen CM, De Napoli IE, Jansen J, Teixeira S, Wilmer MJ, Hoenderop JG, Van den Heuvel LP, Masereeuw R, Stamatialis D. Development of a living membrane comprising a functional human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. Acta Biomaterialia, 14, 22–32, 2015
209. Ficheux A, Ronco C, Brunet P, & Argiles A. The ultrafiltration coefficient: this old 'grand inconnu' in dialysis. Nephrol Dial Transplant, 30, 204-8, 2015
208. Pejchinovski M, Klein J, Ramirez-Torres A, Bitsika V, Mermelekas G, Vlahou A, Mullen W, Mischak H, Jankowski V. Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics Clin Appl, 9, 531-42, 2015
207. Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol Dial Transplant, 30 Suppl 4, 2015
206. Jankowski J, Schanstra JP, Mischak H, Body fluid peptide and protein signatures in diabetic kidney diseases. Nephrol Dial Transplant, 30 Suppl 4, 2015
205. Gajjala PR, Fliser D, Speer T, Jankowski V, Jankowski J. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant,.Apr 10, 2015
204. Filip S, Vougas K, Zoidakis J, Latosinska A, Mullen W, Spasovski G, Mischak H, Vlahou A, Jankowski J. Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine. PLoS One, 10, 2015
203. Rueth M, Lemke HD, Preisinger C, Krieter D, Theelen W, Gajjala PR, Devine E, Zidek W, Jankowski J, Jankowski V. Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites. Acta Physiol (Oxf),May 4, 2015
202. Rroji M, Eloot S, Dhondt A, Van Biesen W, Glorieux G, Neirynck N, Vandennoortgate N, Liabeuf S, Massy Z, Vanholder R. Association of advanced age with concentrations of uraemic toxins in CKD. J Nephrol.Apr 10, 2015
201. Zoccali C, Bolignano D, D'Arrigo G, Dekker FW, Fliser D, Heine GH, Jager KJ,Kanbay M, Mallamaci F, Massy Z, Ortiz A, Parati G, Rossignol P, Tripepi G, Vanholder R, Wiecek A,London G, Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 66, 3-9.2015
200. Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra J, Jankowski J, Mischak H, Argiles A, Vanholder R, Vlahou A, Klein J, New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transplant. Jul 9. 2015
199. Salem S, Jankowski V, Thoning J, Tepel M, Welker P, Raya-Bermudez A, Pineda-Martos C, Rodriguez M, Muñoz-Castañeda JR,Bruck H5, Marx N, Zidek W, Jankowski J. Identification of the “vasoconstriction inhibiting factor” (VIF) a potent endogenous cofactor of angiotensin II acting on the AT2 receptor.Circulation 131, 1426-34, 2015
198. Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.: Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.J Am Soc Nephrol. Jan 14, 2015
197. Holmar J, Uhlin F, Fernström A, Luman M, Jankowski J, Fridolin I. An Optical Method for Serum Calcium and Phosphorus Level Assessment during Hemodialysis. Toxins (Basel). 2015 Feb 27;7(3):719-27.
196. Mischak H, Delles C, Vlahou A, Vanholder R. Proteomic biomarkers in kidney disease: issues in development and implementation.Nat Rev Nephrol. Feb 3, 2015
195. Bhat A, Heinzel A, Mayer B, Perco P, Mühlberger I, Husi H, Merseburger AS, Zoidakis J, Vlahou A, Schanstra JP, Mischak H, Jankowski V.Protein interactome of muscle invasive bladder cancer.PLoS One. Jan 8;10(1),2015
194. Louvet L, Bain D, Büchel J, Stppan S, Passlick-Deetjen J, Massy ZA. Characterisation of calcium phosphate crystals on calcified human aortic vascular smooth muscle cells and potential role of magnesium. PLoS One.Jan 21;10(1),2015
193. Lanza D, Perna AF, Oliva A, Vanholder R, Pletinck A, Guastafierro S, Di Nunzio A, Vigorito C, Capasso G, Jankowski V, Jankowski J, Ingrosso D.Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells.PLoS One. Jan 30;10(1), 2015
2014 192. Stengel B, Combe C, Jacquelinet C, Briancon S, Fouque D, Laville M, Frimat L, Pascal C, Herpe YE, Deleuze JF, Schanstra J, Pisoni RL, Robinson BM, Massy ZA: The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study,Nephrol Dial Transplant, Aug 2014
191. Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA; European Uremic Toxin (EUTox) Work Group. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. Nov;10(6), 2014
190. Barreto FC, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A, Glorieux G, Vanholder R, Massy Z, de Carvalho AB. Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J Bras Nefrol. Jul-Sep;36(3):289-96, 2014
189. Duranton F, Brunet P, Laville M, Landais P, Daurès JP, Mourad G, Bustins M, Argilés A. [Preventing chronic kidney disease in France: Advantages, feasibility  and concerns]. Nephrol Ther. Dec;10(7):492-9, 2014
188. Jankowski J, Westhof T, Vaziri ND, Ingrosso D, Perna AF. Gases as uremic toxins: is there something in the air? Semin Nephrol. Mar;34(2):135-50. 2014
187. Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol, Mar. 2014
186. Nkuipou-Kenfack E,Koeck T, Mischak H, Pich A, Schanstra JP, Zurbig P,
Schumacher B. Proteome analysis in the assessment of ageing. Ageing Res Rev. Sep. 2014
185. Koss M J, Hoffmann J, Nguyen N, Pfister M, Mischak H, Mullen W, Husi H, Rejdak R, Koch F, Jankowski J, Krueger K, Bertelmann T, Klein J, Schanstra JP, Siwy J. Proteomics of vitreous humor of patients with exudative age-related macular degeneration, PloSOne May. 2014
184. Frantzi M, Metzger J,Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk M A, Mischak H, Vlahou A,
Theodorescu D, Merseburger A S. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma, J Proteomics Feb. 2014
183. Filip S, Pontillo C, Schanstra PJ, Vlahou A, Mischak H, Klein J. Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics Oct, 2014
182. Pascual J, Abramowicz D, Cochat P, Claas F, Dudley C, Harden P, Heeman U,Hourmant M, Maggiore U,Salvadori M,Spasovski G,Squif J P,Steiger J,Torres A,Vanholder R,Van Biesen W,Viklicky O,Zeier M,
Nagler E. European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia May, 2014
181. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London G M. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure, Lancet May, 2014
180. Abramowicz D, Cochat P, Claas FH, Heemann U, Pascual J, Dudley C, Harden P, Hourmant M, Maggiore U, Salvadori M, Spasovski G, Squifflet J P, Steiger J, Torres A, Viklicky O, Zeier M, Vanholder R, Van Biese W, Nagler E, European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant Jul, 2014
179. Glorieux G, Hulko M, Speidel R, Brodbeck K, Krause B, Vanholder R.: Looking beyond endotoxin: A comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid.Sci Rep, Sep, 2014
178. Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA, on behalf of the European Uremic Toxin (EUTox) Work Group. Nephrol Ther. Jul, 2014
177. Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stähli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Lüscher TF.:Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J. Mar, 2014.
176. Nkuipou-Kenfack E, Duranton F, Gayrard N, Argilés À, Lundin U, Weinberger KM, Dakna M, Delles C, Mullen W, Husi H, Klein J, Koeck T, Zürbig P, Miachak H.:Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease.PloSOne May, 2014.
175. Boutouyie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM.:Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant Feb, 2014.
174. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Suleymanlar G, Mallamaci F, Zoccali C, London G, Massy ZA.:Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathologiy and the health risk of this process in the clinical scenario? Nephro Dial Transplant Jul, 2014
173. Schulz AM, Terne C, Jankowski V, Cohen G, Schaefer M, Boehringer F, Tepel M, Kunkel D, Zidek W, Jankowski J: Modulation of NADPH oxidase activity by known uraemic retention solutes. Eur J Clin Invest. Aug (2014)
172. Devine E, Krieter DH, Rüth M, Jankovski J, Lemke HD.: Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins (Basel), 2014
171. Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, Drechsler C, Lacatus R, Vanholder R, Nistor I.:Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant Jan, 2014.
170. Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P,Brand K, Delles C, Duranton F, Zurbig P, Jankowski J.: Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant Mar, 2014.
  169. Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P, Wiecek A, Fouque D, Van Biesen W.: A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant. Mar;29(3):490-6, .2014
  168. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G,Fenske W, Hoorn E, Ichai C, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014
  167. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G,Fenske W, Hoorn E, Ichai C, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med., 2014
  166. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G,Fenske W, Hoorn E, Ichai C, Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. Feb, 2014
  165. Poveda J, Sanchez-Nino MD, Glorieux G, Sanz AB, Egido J, Vanholder R, Ortiz A.: p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant, Jan, 2014
  164. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, Mourad G, Daures JP, Weinberger KM, Argiles A.: Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol. Jan, 2014
2013 163. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, Eloot S, Rops A, Van de Voorde J, De Vriese A, van der Vlag J, Brunet P, Van Biesen W, Vanholder R.: Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. J Am Soc Nephrol. Sep, 2013

Ficheux A, Ronco C, Brunet P, Argilés A. The ultrafiltration coefficient: this old 'grand inconnu' in dialysis. Nephrol Dial Transplant. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24362905.

  161. Argilés Á, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One. May 14;8(5)2013
  160. Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A. Vitamin D treatment and mortality in chronic kidney disease: a systematic review  and meta-analysis. Am J Nephrol.;37(3):239-48, 2013
  159. Chudek J, Szotowska M, Karkoszka H, Verbeke F, Trautsolt W, Gumprecht J, Vanholder R, Wiecek A. Genotypes of renin-angiotensin system and plasma adiponectin concentration in kidney transplant patients. Ann Transplant. Nov, 4;18:593-603, 2013
158. Desjardins L, Liabeuf S, Lenglet A, Lemke HD, Vanholder R, Choukroun G.: Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel). Nov, 2013
  157. Jankowski V, Tölle M, Tran TN, van der Giet M, Schuchardt M, Lehmann K, Janke D, Flick B, Ortiz A, Sanchez-Nino MD, Tepel M, Zidek W, Jankowski J.:Identification of a potent endothelium-derived angiogenic factor. PLoS One. Jul, 2013
156. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S.: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. May, 2013
155. Neirynck N, Glorieux G, Boelaert J, Schepers E, Liabeuf S, Dhondt A, Massy Z, Vanholder R: Uremia-Related Oxidative Stress in Leukocytes Is Not Triggered by β2-Microglobulin J Ren Nutr doi 10.1053j.07.2013.
  154. Liabeuf S, Glorieux G, Lenglet A, Diouf M, Schepers E, Desjardins L, Choukroun G, Vanholder R, Massy ZA: Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? PLoS One 8:e67168, 2013
  153. Albalat A, Stalmach A, Bitsika V, Siwy J, Schanstra JP, Petropoulos AD, Vlahou A, Jankowski J, Persson F, Rossing P, Jaskolla TW, Mischak H, Husi H: Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics, 2013
152. Jankowski V, Schulz A, Kretschmer A, Mischak H, Boehringer F, van der Giet M, Janke D, Schuchardt M, Herwig R, Zidek W, Jankowski J: The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates. J Mol Med (Berl), 2013
151. Janke D, Jankowski J, Rüth M, Buschmann I, Lemke HD, Jacobi D, Knaus P, Spindler E, Zidek W, Lehmann K, Jankowski V: The "artificial artery" as in vitro perfusion model. PLos One, March, 2013
  150. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C:Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant, 2013
149. Brettschneider F, Tölle M, von der Giet M, Passlick-Deetjen J, Steppan S, Peter M, Jankowski V, Krause A, Kuhne S, Zidek W, Jankowski J: Removal of Protein-Bound, Hydrophobic Uremic Toxins by a Combined Fractionated Plasma Separation and Adsorption Technique. Artif Organs. Jan, 2013
148. Sicari R, Gargani L, Wiecek A, Covic A, Goldsmith D, Suleymanlar G, Parati G, Ortiz A, Massy Z, Martinez-Castelao A, Lindholm B, Heine GH, Fliser D, Mallamaci F, London G, Zoccali C:The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrol Dial Transplant 2013
147. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO: p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013
2012 146. Neirynck N, Eloot S, Glorieux G, Barreto DV, Barreto FC, Liabeuf S, Lenglet A, Lemke HD, Massy ZA, Vanholder R: Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One. 2012
  145. Spasovski G, Vanholder R: Kidney transplantation in emerging countries: do we know all issues? Minerva Urol Nefrol. Sep.2012
  144. Lenglet A, Liabeuf S, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Brazier M, Choukroun G, Massy ZA: Prognostic implications of plasma myoglobin levels in patients with chronic kidney disease. Int J Artif Organs 2012
  143. Fliser D, Laville M,Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W:A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy.Nephrol Dial Transplant, Dec;2012
  142. Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R, Van Biesen W:Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant. Feb 2012
  141. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Diouf M, Choukroun G, Massy ZA: Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int.82(12):1297-303, 2012.
  140. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M, Kribben A, Nierhaus M,Jankowski V, Zidek W, Jankowski J.: Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. J Am Soc Nephrol ;35(1):31-9, 2012
  139. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest.42,1027-10.36, 2012
  138. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and Pathologic Concentrations of Uremic Toxins. J Am Soc Nephrol, 23,1258-1270,2012
  137. Vanholder R, Eloot S, Schepers E, Neirynck N,Glorieux G, Massy Z.An Obituary for GFR as the main marker for kidney function? Semin Dial Jan-Feb;25(1):9-14, 2012
  136. Calaf R, Cerini C, Genovesio C, Verhaeghe P, Jourde-Chiche N, Berge-Lefranc D, Gondouin B, Dou L, Morange S, Argiles A, Rathelot P, Dignat-George F, Brunet P, Charpiot P: Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. J Chromatogr B Analyt Technol Biomed Life, Jan 879(23): 879:2281-2286, 2012
2011 135. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant, , 26:2624-2630, 2011
134. Ficheux A, Gayrard N, Szwarc I, Andress D, Soullier S, Duny Y, Goubert G, Thomas M, Bismuth-Mondolfo J, Daures JP, Brunet P, Servel MF, Argiles A: The use of SDS-PAGE scanning of spent dialysate to assess uraemic toxin removal by dialysis. Nephrol Dial Transplant 2011
133. Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J: Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects.FASEB J. 2011
132. Ficheux A, Kerr PG, Brunet P, Argiles A: The ultrafiltration coefficient of a dialyser (KUF) is not a fixed value, and it follows a parabolic function: the new concept of KUF max. Nephrol Dial Transplant, 2011
131. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtey S: Does uremia cause vascular dysfunction? Kidney Blood Press Res, 2011
130. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, Massy Z, Evenepoel P. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant, 2011
129. Spasovski G, Ortiz A, Vanholder R, El Nahas M. Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. Proteomics Clin Appl, 2011
128. Heemann U, Abramowicz D, Spasovski G, Vanholder R. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant, 2011
127. Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W,
Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol, 2011
126. Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R, Van Biesen W. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant, Feb, 2011 .
125. Schepers E, Barreto DV, Liabeuf S,Glorieux G,Eloot S, Barreto FC, Massy Z, Vanholder R,. Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. Clin J Am Soc Nephrol, 2011
124. Jankowski V, Toelle M, Santos RA, Guenthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, SampaioWO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis.FASEB ,2011
123. Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, Vanholder R, Choukroun G, Massay Z, Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease. Nephrol, 2011
122. Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, Massy ZA. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens, 29 (4): 783-790, 2011
2010 121. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia? Blood Purif. 2010;
120. Vanholder R, Bammes B, de Loor H,Glorieux G, Meijers B, Schepers E, Massay Z, Evenepoel P. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant, 2010
119. Hergeth-Rosenthal S, Quellmann T, Linden C, Hollenbeck M, Jankowski V, Kribben A. How does late nephrological co-management impact chronic kedney disease? - an observational study. Int J Clin Pract, 2010
118. Meert N, Waterloos MA, Van Landschoot M, Dhondt A, Ledebo I, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs, 2010
117. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant, 2010
116. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM, Vanholder R. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Trans. Sep 08 2010 (online)
115. Massy ZA, Barreto DV, Barreto FC, Vanholder R. Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors.Atherosclerosis 211(2):381-3
114. Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, Weissinger E, Haubitz M, Mischak H, Herget-Rosenthal S. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int Sep 8 2010
113. Schepers E, Glorieux G, Jankowski V, Dhondt A, Jankowski J, Vanholder R. Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrol Dial Transplant 25(8):2636-44
112. Mischak H. Allmaier G. Apweiler R. Attwood T. Baumann M. Benigni A. Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sanchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 46(2):46ps42
111. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, Dakna M. Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M. Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M. Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neususs C, Novak J. PeterK, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger E, Mischak H, Schmitt-Kopplin P. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics Sep 10
110. Ficheux A, Gayrard N, Szwarc I, Soullier S, Bismuth-Mondolfo J, Brunet P, Servel MF, Argilés A. Use of spent dialysate analysis to estimate blood levels of uraemic solutes without blood sampling: urea. Nephrol Dial Transplant, 2010
109. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010
108. Verbeke F, Haug U, Dhondt A, Beck W, Schnell A, Dietrich R, Deppisch R, Vanholder R. The role of polymer surface degradation and barium sulphate release in the pathogenesis of catheter-related infection. Nephrol Dial Transplant 2010
107. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD,Tribouilloy C, Choukroun G, Vanholder R, Massy ZA. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int, 2010
106. Pletinck A, Consoli C, Van Landschoot M, Steppan S, Topley N,Passlick-Deetjen J, Vanholder R, Van Biesen, W . Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats. Nephrol Dial Transplant 25:1688-96
105. Schepers E, Glorieux G, Jankowski V, Dhondt A, Jankowski J, Vanholder R, . Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrol Dial Transplant, 2010
2009 104. Perna AF, Ingrosso D, Violetti E, Luciano MG, Sepe I, Lanza D, Capasso R, Ascione E, Raiola I, Lombardi C, Stenvinkel P, Massy ZA, De Santo NG. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 22:351-356
103. Mischak H, Massy ZA, Jankowski J. Proteomics in uremia and renal disease. Semin Dial 22:409-416
102. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial 22:405-408
101. Jankowski V, Gunthner T, Herget-Rosenthal S, Zidek W, Jankowski J. Dinucleoside polyphosphates and uremia. Semin Dial 22:396-399
100. Herget-Rosenthal S, Glorieux G, Jankowski J, Jankowski V. Uremic toxins in acute kidney injury. Semin Dial 22:445-448
99. Gunthner T, Jankowski V, Kretschmer A, Nierhaus M, van der Giet M, Zidek W, Jankowski J. Endothelium and vascular smooth muscle cells in the context of uremia. Semin Dial 22:428-432
98. Drueke TB, Massy ZA. Beta2-microglobulin. Semin Dial 22:378-380
97. Barreto FC, Barreto DV, Liabeuf S, Drueke TB, Massy ZA. Effects of uremic toxins on vascular and bone remodeling. Semin Dial 22:433-437
96. Argiles A, Vanholder R. Chronic kidney disease-related mineral and bone disorders.Nephron Clin. Pract 2009;112: c128-c136
95. Vanholder R, Massy ZA. Progress in uemic toxin research: an introduction. Semin Dial 200;22 321-322
94. Vanholder R, Abou-Deif O, Argiles A et al. The role of EUTox in uremic toxin research. Semin Dial 200;22 323-328
93. Jourde-Chiche N, Dou L, Cerini C,Georg F, Vanholder R, Brunet P. Protein-bound toxins-update. Semin Dial 200;22 334-339
92. De Deyn PP, Vanholder R, Eloot S, Glorieux G. Guanidino compaunds as uremic (neuro)toxins. Semin Dial 200;22 340-345
91. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009;22 4357-362
90. Luttropp K, Lindholm B, Carrero JJ et al. Genetics/Genomics in chronic kidney desease-torwards personalized medicine? Semin Dial 200;22 417-422
89. Glorieux G, Cohne G, Jankowski J, Vanholder R.Platelet/Leukocyte activation inflammation and uremia. Semin Dial 200;22 423-427
88. Vanholder R, Argiles A, Beige J et al. Conservative treatment of the uremic syndrome. Semin Dial 200;22 449-453
87. Jankowski V, van der Giet M, Mischak H, Morgan M, Zidek W, Jankowski J. Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.  Br J Pharmacol, 7:1142-1153,2009
  86. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant, 24: 348-354, 2009
85. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant, 24: 562-570, 2009
84. Glorieux G, Schepers E, Schindler R, Lemke HD, Verbeke F, Dhondt A, Lameire N, Vanholder R. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant, 24: 548-554, 2009
83. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, Vanholder RC, Dominiczak AF, Chen YC, Mischak H, Bode C, Peter K.Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients.J Proteome Res, 2: 335-345, 2009
2008 82. Vlahou A, Schanstra J, Frokiaer J, El Nahas M, Spasovski G, Mischak H, Domon B, Allmaier G, Bongcam-Rudloff E, Attwood T.European Kidney and Urine Proteomics Network.J Proteomics, 490-492, 2008  
81. Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Herget-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.Proteomics. Clinical applications, 964-973, 2008
80. Krieter DH, Lemke HD, Wanner C. A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal. Artif Organs, 32, 547-554, 2008 
  79. Bender TO, Witowski J, Aufricht C, Endemann M, Frei U, Passlick-Deetjen J,  Jorres A. Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis. Pediatr Nephrol, 23: 1537-1543, 2008 
  78. Vanholder R, De Deyn PP, Van Biesen W, Lameire N. Marconi revisited: from kidney to brain--two organ systems communicating at long distance. J Am Soc Nephrol, 19: 1253-1255, 2008
77. Zoccali C, Abramowicz D, Cannata-Andia JB, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, McLeod A, Lindley E, Locatelli F, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Vanholder R. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant, 23: 2162-2166, 2008
76. Schiffer E, Mischak H, Vanholder RC: Exploring the uremic toxins using proteomic technologies. Contrib Nephrol, 160: 159-171, 2008
  75. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int: 73, 391-398, 2008   
74. Ivanovski O, Szumilak D, Nguyen-Khoa T, Nikolov IG, Joki N, Mothu N, Maizel,J, Westenfeld R, Ketteler M, Lacour B, Drueke TB, Massy ZA: Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol 179: 1631-1636, 2008
73. Phan O, Ivanovski O, Nikolov IG, Joki N, Maizel J, Louvet L, Chasseraud M, Nguyen-Khoa T, Lacour B, DruekeTB, Massy ZA: Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant: 23: 82-90, 2008 
  72. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J.  A Bench to Bedside View of Uremic Toxins: J Am Soc Nephrol, 19: 863-870, 2008
71. Taes YE, Marescau B, De Vriese A, De Deyn PP, Schepers E, Vanholder R, Delanghe JR: Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. Nephrol Dial Transplant, 23: 1330-1335, 2008
70. Jankowski V, Patzak A, Herget-Rosenthal S, Tran TN, Lai EY, Günthner T, Buschmann I, Zidek W, Jankowski J: Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. J Mol Med 83:333-340, 2008
   69. Stenvinkel P, Carrero JJ, AxelssonJ, Lindholm B, Heimburger O, MassyZ: Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin J Am Soc Nephrol 3: 505-521, 2008
2007 68. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes.   Am J Kidney Dis 50: 279-288, 2007 
67. Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, Vanholder R: Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 41: 698-703, 2007
  66. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der Giet M, Tölle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. Kidney Int 71:994-1000,2007
65. Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke T, Mischak H, Spasovski G, Massy Z, Jankowski J: Review on uraemic solutes II-variability in reported concentrations: causes and consequences. Nephrol Dial Transplant; 22: 3115-3121, 2007
64. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH: Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. Nephrol Dial Transplant; 22: 3381-3390, 2007
63. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 31: 600-611, 2007
  62. Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B: Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta, 379, 87-94, 2007
  61. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, TranTN, TepelM, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J: Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27, 297-302, 2007
60. Massy ZA, Slama M, Tribouilloy C, Drueke TB: Animal models-what they can tell us about vascular calcification in CKD. Semin Dial.  Mar-Apr;20(2):110-2, 2007
  59. Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominizak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser DF, Jankowski J, Julian BA, Kolch W, Massy Z, Neususs C, Novak J, Peter K, Rossing K, Schanstra JP, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T: Clinical Proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 1: 148-156, 2007
  58. Ivanovski O, Nikolov IG, Drueke TB, Massy ZA: Atherosclerosis and vascular calcification in uraemia - a new experimental model. Prilozi, 28: 11-24, 2007
  57. Drueke TB, Eckardt K-U, Scherhag A: Chronic kidney disease, anemia, and epoetin. N Engl J Med, 356: 959, 2007
56. D.Fliser, J Novak, V Thongboonkerd, À. Argilés, V Jankowski , M A. Girolami , J Jankowski, H Mischak: Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol., 18(4):1057-71, 2007
2006 55. Nikolov IG, Joki N, Maizel J, Lacour B, Drueke TB, Massy ZA: Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl. Dec;(105):S16-23, 2006
54. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med, 355: 2071-2084, 2006
53. Nikolov I, Joki N, Drueke T, Massy Z: Beyond phosphate--role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant 21: 3354-3357, 2006
52. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellstrom B, Heimburger O, Lindholm B, Alvestrand A: Statin treatment and diabetes affect Myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1: 281- 287, 2006
51. Torremans A, Marescau B, Kranzlin B, Gretz N, Billiouw JM, Vanholder R,  De Smet R, Bouwman K, Brouns R, De Deyn PP: Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition. Kidney Int 69, 2003-2012, 2006.
50. Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T, Mischak H, Drüeke TB, Lacour B,. Massy  ZA: Effects of oral vitamin C supplementation in hemodialysis patients - a proteomic assessment. Proteomic 6: 993-1000, 2006
2005 49. Drueke TB, Massy ZA: Intravenous iron: how much is too much? J Am Soc Nephrol 16:2833-2835, 2005.
48. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J: Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nature Med 11: 223-227, 2005
47. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Eltze E, Bettendorf O, Wuelfing C, Semjonov A. Capillary electrophoresis coupled to mass spectrometry as a tool to define prostate cancer biomarkers: a preliminary study. Electrophoresis 27: 2797-2808, 2005
46. Meier M, Kaiser T, Herrmann A, Knuppel S, Hillmann M, Koester P, Haller H, Fliser D, Mischak H. Identification of urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complicat 19: 223-232, 2005
45. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 67:1566-1575, 2005
44. Ivanovski O, Szumilak D, Nguyen-Khoa T, Dechaux M, Massy ZA, Phan O, Mothu N, Lacour B, Drueke TB, Muntzel M: Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 180:271-276, 2005
43. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drueke TB, Massy ZA: The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 67:2288-2294, 2005
42. Jankowski V, Vanholder R, Henning L, Karadogan S, Zidek W, Schluter H, Jankowski J: Isolation and quantification of dinucleoside polyphosphates by using monolithic reversed phase chromatography columns. J Chromatogr B Analyt Technol Biomed Life Sci  819:131-139, 2005
41. Jankowski V, Vanholder R, van der Giet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J: Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46, 591-597, 2005
40. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS: Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol  16:109-116, 2005
39. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J,  Westenfeld R, Ketteler M,  Meert N, Maizel J, Nikolov I, Vanholder R, Lacour B, Drueke TB, Massy ZA: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E deficient (apoE-/-)mice. Circulation 112: 2875-2822, 2005
38. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M and Nordfors L: Low serum fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 67: 2383-2392, 2005
37. Vanholder R, Del Canizo JF, Sauer IM, Stegmayr B: The European artificial organ scene: present status. Artif Organs 29:498-506, 2005
36. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant  20:1048-1056, 2005
35. Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, Walden M, Mischak H, Fliser D, Just I, Marshall AG. Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 77: 7163-7171, 2005
2004 34. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G, De Smet R, Vanholder R, Dignat-George F, Sampol J, Berland Y, Brunet P: P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92:140-150, 2004
33. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65:442-451, 2004
32. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 66:1873-1880, 2004
31. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 65:2184-2192, 2004
30. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knüppel S, Haller H, Fliser D. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci 107: 485-495, 2004
29. Ivanovski N, Stojceva-Taneva O, Grozdanovski R, Boskovska M, Drueke TB, Massy ZA: Short-term effect of folic acid supplementation in renal transplant recipients and chronic kidney disease patients with comparable renal function impairment. Nephrologie 25:301-303, 2004
28. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 65: 2426-2434, 2004
27. Massy ZA, Fumeron C, Borderie D, Tuppin P, Nguyen-Khoa T, Benoit MO, Jacquot C, Buisson C, Drueke TB, Ekindjian OG, Lacour B, Iliou MC: Increased pasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective study. J Am Soc Nephrol  15:470-476, 2004
26. Kaiser T, Wittke S, Krebs R, Bartel S, Fliser D, Mischak H,Weissinger EM. Weissinger EM. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide recognition in body fluids for clinical use. Electrophoresis 25: 2044-2055, 2004
25. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Andersson S, Schalling M, Barany P, Lindholm L, Nordfors L: Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281, 2004
24. Torremans A, D'Hooge R, Van d, V, Marescau B, Vanholder R, Lameire N, De Deyn PP, Van Bogaert PP: Effect of NaCN on currents evoked by uremic retention solutes in dissociated mouse neurons. Brain Res  1008:107-112, 2004
23. Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC: Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant  19:3068-3077, 2004
2003 22. Canalejo A, Almaden Y, De Smet R, Glorieux G, Garfia B, Luque F, Vanholder R, Rodriguez M: Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. Kidney Int 63:732-737, 2003
21. Wittke S, Fliser D, Haubitz M,Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P,  Haller H, Kaiser T, Mischak H, Weissinger EM. Determination of peptides and proteins in human urine with capillary electrophoresis mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 1013: 173-181, 2003
20. De Deyn PP, Vanholder R, D'Hooge R: Nitric oxide in uremia: effects of several potentially toxic guanidino compounds. Kidney Int 84 (Suppl 63): S25-S28, 2003
19. Kaiser T, Hermann A, Kielstein JT, Wittke S, Bartel S, Krebs K, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Weissinger EM, Fliser D, Mischak H.Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids . J Chromatogr A 1013: 157-171, 2003
18. D'Hooge R, Van De Vijver G, V, Van Bogaert PP, Marescau B, Vanholder R, De Deyn PP: Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 63:1764-1775, 2003
17. F Locatelli, B Canaud, K Eckardt, P Stenvinkel, C Wanner, C Zoccali: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transpl 18: 1272-1280, 2003
16. F Locatelli, B Canaud, K Eckardt, P Stenvinkel, C Wanner, C Zoccali: The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transpl 18: 1716-1725, 2003
15. Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant  18:153-157, 2003
14. Torremans A, Marescau B, Vanholder R, De Smet R, Billiouw JM, De Deyn PP: The low nanomolar levels of N G-monomethylarginine in serum and urine of patients with chronic renal insufficiency are not significantly different from control levels. Amino Acids 24:375-381, 2003
13. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63:1934-1943, 2003
12. Vanholder RC, Glorieux G, De Smet R, De Deyn PP: Low water-soluble uremic toxins. Adv Ren Replace Ther  10:257-269, 2003
11. Vicca S, Massy ZA, Hennequin C, Rihane D, Drueke TB, Lacour B: Apoptotic pathways involved in U937 cells exposed to LDL oxidized by hypochlorous acid. Free Radic Biol Med 35:603-615, 2003
10. Vicca S, Massy ZA, Hennequin C, Rihane D, Nguyen-Khoa T, Drueke TB, Lacour B: New insights into the effects of the protein moiety of oxidized LDL (oxLDL). Kidney Int 84 (Suppl 63): S125-S127, 2003
9. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem  49:470-478, 2003
2002 8. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, De Smet R, Vanholder R, Sampol J, Berland Y: P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 62:1999-2009, 2002
7. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
6. Drueke TB, Massy ZA: Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif. 20:494-497, 2002
5. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, Drueke T, Massy ZA: Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant  17:865-870, 2002
4. P. Stenvinkel, C Wanner, T Metzger, O Heimbürger, F Mallamaci, G Tripepi, L Malatino, C Zoccali. Inflammation and outcome in end-stage renal disease: impact of gender. Kidney Int 62: 1791-1798, 2002
2001 3. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. Int J Artif Organs 24:695-725, 2001
2000 2. Vicca S, Hennequin C, Nguyen-Khoa T, Massy ZA, Descamps-Latscha B, Drueke TB, Lacour B: Caspase-dependent apoptosis in THP-1 cells exposed to oxidized low-density lipoproteins. Biochem Biophys Res Commun  273:948-954, 2000
1999 1. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy ZA: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 56:2292-2296, 1999

go top